Zhengye Biotechnology Holding (ZYBT) Total Current Liabilities (2023 - 2025)

Zhengye Biotechnology Holding (ZYBT) has reported Total Current Liabilities for 3 consecutive years, with $17.0 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Total Current Liabilities fell 10.22% year-over-year to $17.0 million in Q4 2025; TTM through Dec 2025 was $17.0 million, a 10.22% decrease from a year earlier, with the FY2025 full-year figure at $17.2 million, down 7.46% from the prior year.
• Total Current Liabilities was $17.0 million for Q4 2025 at Zhengye Biotechnology Holding, down from $18.8 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $20.9 million in Q4 2023 and troughed at $17.0 million in Q4 2025.
• A 3-year average of $18.9 million and a median of $18.9 million in 2024 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities decreased 9.32% in 2024 and slipped 10.22% in 2025, its largest moves.
• Over 3 years, Total Current Liabilities stood at $20.9 million in 2023, then declined by 9.32% to $18.9 million in 2024, then fell by 10.22% to $17.0 million in 2025.
• The last three Total Current Liabilities figures came in at $17.0 million (Q4 2025), $18.8 million (Q2 2025), and $18.9 million (Q4 2024), per Business Quant data.